| Autor: |
Kucharczyk, Monika, Cudzik-Dziurzyńska, Joanna, Błaszczyk, Aleksandra, Lewitowicz, Piotr, Kręcisz, Beata |
| Předmět: |
|
| Zdroj: |
Family Medicine Forum / Forum Medycyny Rodzinnej; 2024, Vol. 18 Issue 4, p141-145, 5p |
| Abstrakt: |
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory diseases. Recently, new therapeutic options for patients with moderate-to-severe AD have emerged, such as dupilumab or janus kinase inhibitors. This paper presents the case of a patient who developed a rare exanthematous skin adverse reaction after the administration of the initial dose of dupilumab. Aim of the study: To showcase new therapeutic alternatives for patients with moderate-to- -severe AD, such as dupilumab or Janus kinase inhibitors. Material and methods: A retrospective review of the procedure and patient follow-up was undertaken. Case report: A 43-year-old female with severe atopic dermatitis, was admitted to the Department of Dermatology. The patient presented with severe erythematous lesions on the lateral surfaces of the trunk, and upper and lower extremities, accompanied by intense pruritis, which appeared 24 hours after starting dupilumab treatment. Because of the suspicion of adverse drug reaction further treatment with dupilumab was suspended. Improvement of skin lesions was observed within a few days. Due to persistent symptoms of severe AD patient was qualified for upadacitinib - Janus kinase 1 inhibitor (JAK-1) with a highly successful clinical response and continued treatment without any adverse events. Conclusions: The take-home message is that even a relatively safe biologic therapy can cause the occurrence of undesirable symptoms. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
